Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Therapy

• Published in: Clinical lung cancer Vol. 16; no. 4; pp. 320 - 324
• Main Authors: Lankheet, Nienke A.G., Schaake, Eva E., Burgers, Sjaak A., van Pel, Renée, Beijnen, Jos H., Huitema, Alwin D.R., Klomp, Houke
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2015
• Subjects: Aged; Antineoplastic Agents - pharmacokinetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Chromatography, High Pressure Liquid - methods; Erlotinib Hydrochloride - pharmacokinetics; Female; Hematology, Oncology and Palliative Medicine; Humans; Intratumoral drug concentration; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Male; Middle Aged; Neoadjuvant Therapy; Neoadjuvant treatment; Pharmacokinetics; Pulmonary/Respiratory; Surgical resection; Tandem Mass Spectrometry; Time Factors; Tissue Distribution; Tyrosine kinase inhibitor; Surgical resection; Intratumoral drug concentration; Pharmacokinetics; Tyrosine kinase inhibitor; Neoadjuvant treatment

The purpose of this exploratory study was to investigate lung tumor tissue erlotinib concentrations after neoadjuvant therapy for non–small-cell lung cancer. Thirteen evaluable patients were treated preoperatively with erlotinib up to 48 hours before surgery. The lung tumor tissue erlotinib levels w...